aod9604 fat loss clinical trials efficacy side effects AOD 9604 – The Fat-Burning Peptide: Benefits, Mechanism & Safety AOD-9604 vs MOTS-c vs Tesamorelin

What testing information is available for AOD 9604

doi: 10.3389/fnut.2024.1433390 Received 15 May 2024 Accepted 30 September 2024 Published 30 October 2024 Volume 11 - 2024 Edited by Anna Maria Aloisi, University of Siena, Italy Reviewed by Vahidreza Ostadmohammadi, Kashan University of Medical Sciences, Iran Anna Petroni, University of Siena, Italy Thomas Herdegen, University of Kiel, Germany Updates Copyright 2024 Hajhashemy, Golpour-Hamedani, Eshaghian, Sadeghi, Khorvash and Askari

ERK2 controls lipolysis by phosphorylating ADRB3 (at Ser247) and potentially other proteins, that regulate cAMP levels, such as ADCY6 and PDE4A/B 37

You slowly inject 2mL of Bacteriostatic Water into the vial

You may experience fatigue, shortness of breath, pale skin, weakness, or tingling in your hands and feet